Literature DB >> 24374461

Histopathological and clinical findings in renal transplants with Banff type II and III acute cellular rejection without tubulointerstitial infiltrates.

Verena Bröcker1, Muhannad Hirzallah, Wilfried Gwinner, Clemens Luitpold Bockmeyer, Juliane Wittig, Stephanie Zell, Putri Andina Agustian, Anke Schwarz, Tina Ganzenmüller, Eva Zilian, Stephan Immenschuh, Jan Ulrich Becker.   

Abstract

According to the Banff guidelines for renal transplants, pure endothelialitis without any tubulointerstitial infiltrates (with the Banff components v ≥ 1, i0, t0) has to be called acute cellular rejection (ACR). The pathophysiology of this rare lesion abbreviated as v_only is currently unclear, as well as its clinical, serological, and prognostic implications. Therefore, we conducted this retrospective comparative study. We compared all 23 biopsies with v_only from Hannover Medical School between 2003 and 2010 with 23 matched biopsies with the Banff components v ≥ 1, i ≥ 1, and t ≥ 1 (v_plus) and 23 biopsies with v0, i0, and t0 (v0i0t0). Serological (available in 10, 11, and 14 patients, respectively), histological, and clinical data were compared. Of all biopsies, 0.4 % had findings of v_only. v_only, v_plus, and v0i0t0 only showed minimal differences in the Banff components apart from the cohort-defining components. Endothelialitis in v_only more frequently involved the arcuate arteries than the smaller preglomerular vessels compared to v_plus and vice versa. Combining histopathological data and serological data, v_only more frequently showed criteria for acute humoral rejection than v0i0t0 (albeit not persistent after the Bonferroni-Holm correction in pairwise comparisons), while there was no difference between v_only and v_plus. No difference could be demonstrated regarding clinical presentation at biopsy or outcome. Our results show minimal differences regarding clinical presentation, outcome, and histological features between v_only and v_plus. Patients with v_only should be thoroughly investigated for evidence of acute humoral rejection.

Entities:  

Mesh:

Year:  2013        PMID: 24374461     DOI: 10.1007/s00428-013-1487-0

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  24 in total

Review 1.  Acute vascular rejection after renal transplantation and isolated v-lesion.

Authors:  Tomokazu Shimizu; Tatsu Tanabe; Hiroki Shirakawa; Kazuya Omoto; Hideki Ishida; Kazunari Tanabe
Journal:  Clin Transplant       Date:  2012-07       Impact factor: 2.863

2.  Molecular diagnosis of T cell-mediated rejection in human kidney transplant biopsies.

Authors:  J Reeve; J Sellarés; M Mengel; B Sis; A Skene; L Hidalgo; D G de Freitas; K S Famulski; P F Halloran
Journal:  Am J Transplant       Date:  2013-01-28       Impact factor: 8.086

3.  Heterogeneity in endothelial cells from large vessels and microvessels.

Authors:  S Kumar; D C West; A Ager
Journal:  Differentiation       Date:  1987       Impact factor: 3.880

4.  Why rejections are not biopsy proven: frequency and reasons.

Authors:  F Fleiner; P Glander; L Fritsche; H-H Neumayer; K Budde
Journal:  Transplant Proc       Date:  2010-12       Impact factor: 1.066

5.  A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.

Authors:  A S Levey; J P Bosch; J B Lewis; T Greene; N Rogers; D Roth
Journal:  Ann Intern Med       Date:  1999-03-16       Impact factor: 25.391

6.  Pathologic features of acute renal allograft rejection associated with donor-specific antibody, Analysis using the Banff grading schema.

Authors:  K Trpkov; P Campbell; F Pazderka; S Cockfield; K Solez; P F Halloran
Journal:  Transplantation       Date:  1996-06-15       Impact factor: 4.939

7.  Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups.

Authors:  B Sis; M Mengel; M Haas; R B Colvin; P F Halloran; L C Racusen; K Solez; W M Baldwin; E R Bracamonte; V Broecker; F Cosio; A J Demetris; C Drachenberg; G Einecke; J Gloor; D Glotz; E Kraus; C Legendre; H Liapis; R B Mannon; B J Nankivell; V Nickeleit; J C Papadimitriou; P Randhawa; H Regele; K Renaudin; E R Rodriguez; D Seron; S Seshan; M Suthanthiran; B A Wasowska; A Zachary; A Zeevi
Journal:  Am J Transplant       Date:  2010-01-29       Impact factor: 8.086

8.  Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection.

Authors:  Lorraine C Racusen; Robert B Colvin; Kim Solez; Michael J Mihatsch; Philip F Halloran; Patricia M Campbell; Michael J Cecka; Jean-Pierre Cosyns; Anthony J Demetris; Michael C Fishbein; Agnes Fogo; Peter Furness; Ian W Gibson; Denis Glotz; Pekka Hayry; Lawrence Hunsickern; Michael Kashgarian; Ronald Kerman; Alex J Magil; Robert Montgomery; Kunio Morozumi; Volker Nickeleit; Parmjeet Randhawa; Heinz Regele; Daniel Seron; Surya Seshan; Stale Sund; Kiril Trpkov
Journal:  Am J Transplant       Date:  2003-06       Impact factor: 8.086

9.  Potential impact of microarray diagnosis of T cell-mediated rejection in kidney transplants: The INTERCOM study.

Authors:  P F Halloran; A B Pereira; J Chang; A Matas; M Picton; D De Freitas; J Bromberg; D Serón; J Sellarés; G Einecke; J Reeve
Journal:  Am J Transplant       Date:  2013-08-05       Impact factor: 8.086

10.  Antibody-mediated vascular rejection of kidney allografts: a population-based study.

Authors:  Carmen Lefaucheur; Alexandre Loupy; Dewi Vernerey; Jean-Paul Duong-Van-Huyen; Caroline Suberbielle; Dany Anglicheau; Jérôme Vérine; Thibaut Beuscart; Dominique Nochy; Patrick Bruneval; Dominique Charron; Michel Delahousse; Jean-Philippe Empana; Gary S Hill; Denis Glotz; Christophe Legendre; Xavier Jouven
Journal:  Lancet       Date:  2012-11-23       Impact factor: 79.321

View more
  4 in total

1.  Reassessing the Significance of Intimal Arteritis in Kidney Transplant Biopsy Specimens.

Authors:  Israel D R Salazar; Maribel Merino López; Jessica Chang; Philip F Halloran
Journal:  J Am Soc Nephrol       Date:  2015-04-27       Impact factor: 10.121

Review 2.  Proteomics for rejection diagnosis in renal transplant patients: Where are we now?

Authors:  Wilfried Gwinner; Jochen Metzger; Holger Husi; David Marx
Journal:  World J Transplant       Date:  2016-03-24

Review 3.  Current status of pediatric renal transplant pathology.

Authors:  Jan U Becker
Journal:  Pediatr Nephrol       Date:  2016-05-24       Impact factor: 3.714

4.  Rituximab and Monitoring Strategies for Late Antibody-Mediated Rejection After Kidney Transplantation.

Authors:  Sandesh Parajuli; Didier A Mandelbrot; Brenda Muth; Maha Mohamed; Neetika Garg; Fahad Aziz; Robert R Redfield; Weixiong Zhong; Brad C Astor; Arjang Djamali
Journal:  Transplant Direct       Date:  2017-10-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.